- Research article
- Open Access
Primary thymus tumors: retrospective case analysis at a reference center in Latin America, 2011–2019
BMC Cancer volume 21, Article number: 279 (2021)
Thymic tumors are unusual neoplasms, representing 0.2 to 1.5% of tumors in humans, but correspond to 20% of mediastinal tumors and 50% of those that occur in the anterior mediastinum. They tend to appear around the fourth and fifth decades of life without gender predilection. Up to 30% of patients are asymptomatic, therefore many are incidentally diagnosed. Radical thymectomy is the treatment of choice with high survival rates when detected in the early stages.
This was a retrospective descriptive study, including 18 adult patients’ diagnosis of thymic neoplasm, who were managed with surgical resection from 2011 to 2019. Information about demographics, clinical characteristics, imaging findings, surgical and medical management, plus histological findings was obtained and reported.
18 patients with thymic tumors were included, of which specific histologic studies reveled thymomas, carcinomas, neuroendocrine tumors, thymolipoma and thymic cyst. Mean age was 52.7 years, with a predominance of male population. The main symptom was dyspnea, followed by cough and chest pain. Paraneoplastic syndromes such as myasthenia gravis, aplastic anemia and Cushing syndrome were reported. 89% of cases were treated by radical thymectomy alone, while only 2 cases required chemotherapy and radiotherapy. There were no surgical complications. Mean hospital stay length was 11. 9 days, with only 1 mortality during hospital admission. 5-year survival rate was 81%.
The treatment of choice is radical thymectomy, which has been shown to positively impact patient mortality. Early detection is key to improve patient outcomes.
Thymus tumors include neoplasms that arise from or differ from thymic cell constituents, comprising thymic epithelial tumors (thymomas, thymic carcinomas, neuroendocrine tumors), germ cell, lymphoid and hematopoietic, and mesenchymal tumors .
They are unusual neoplasms, representing 0.2 to 1.5% of tumors in humans, with an incidence of 0.1 to 0.5 cases per 100,000 individuals per year in the United States . However, thymus tumors correspond to 20% of mediastinal tumors and 50% of those that occur in the anterior mediastinum . They tend to appear around the fourth and fifth decades of life without gender predilection . Approximately 25 to 30% of patients are asymptomatic, and are incidentally diagnosed, 50% being revealed by chest computed tomography (CT) . When symptomatic, 40% of patients present with local symptoms triggered by mass effect (mainly chest pain, cough, snoring and dyspnea), 30% report constitutional symptoms (weight loss, fever and night sweats), and 30–50% present with paraneoplastic syndromes [4, 6].
When the tumor is found by imaging modalities, of which contrast enhanced chest CT scan is the image of choice, the next steps are to characterize and stage the lesion, stablishing the degree of local invasion, the presence of lymphadenopathy and distant dissemination. Hence allowing the identification of patients who benefit from surgical management as compared to those who require other types of interventions . In fact, the National Comprehensive Cancer Network (NCCN) guidelines classifies thymic tumors into three clinical categories: localized and resectable, locally advanced and unresectable, and metastatic; a combination of surgical protocols, radiotherapy and/or chemotherapy is warranted for the last two groups, while surgery is sufficient to treat the first category .
The objective of this study is to describe the demographic, clinical, radiological and histological characteristics of 18 patients with thymic tumors, who were taken to surgical tumor resection at Fundación Valle del Lili, a high complexity institution in Cali-Colombia, between 2011 and 2019.
This was a descriptive study based on clinical records of adult patients (≥ 18 years old) who had a diagnosis of thymic neoplasm and were treated at our institution from 2011 to 2019. Information about demographics, clinical characteristics, imaging findings, surgical and medical management, plus histological findings was obtained. Patients were followed up to December 2019 and the survival curve was estimated using the Kaplan-Meier method. This study was approved by the ethics committee of our institution and was developed according to the Helsinki Declaration of 1964.
Demographic and clinical characteristics
18 patients with diagnosis of thymic tumor were treated at our institution between 2011 and 2019; 11 male (61%) and 7 females (39%), with a mean age of 52.7 years (±16.6). 3 patients were asymptomatic (16.6%). The remaining patients presented with constitutional symptoms (61.1%) of which the most common was weight loss, or local symptoms (55.5%) being the most frequent dyspnea, cough and chest pain in decreasing order. Paraneoplastic syndromes presented in 27.7% of patients, of which 2 had myasthenia gravis, 1 had a non-myastheniform neuromuscular disorder, 1 had red blood cell (RBC) aplasia and 1 had Cushing syndrome (Table 1).
Chest imaging showed that 14 cases (77.7%) involved the anterior mediastinum, 2 cases (11%) compromised the left parahiliar region, 1 case (5.5%) the middle mediastinum and 1 case (5.5%) the left prevascular space (Fig. 1). The longest side of the tumors had a mean of 7.5 cm (± 5.37). Tumor density was reported in 13 patients; it was heterogenous in 53.8% of patients with calcifications in 30.8%. Only one patient presented with pleural effusion.
Most patients had a localized disease; using the Masaoka-Koga and TNM staging system for malignant tumors, 13 patients (76.4%) were classified as stage I for both systems, 3 cases (17.6%) stage IV and IVB respectively (1 patient had metastasis in deep intrathoracic/cervical lymph nodes and 2 had distant metastasis) and 1 patient (6.2%) was classified as stage III (MK) or stage II (TNM) cancer due to invasion of the pericardium. In one patient the information was not available (Table 2).
None of the cases had a biopsy performed prior to the surgical resection, which was done by thoracoscopy in 12 cases (66.6%), sternotomy in 5 patients (27.8%) and thoracotomy was performed in 1 case (5.5%). There were no intra or postsurgical complications, particularly pneumothorax or phrenic nerve lesion. Median blood loss was retrieved for 16 patients, with a median of 75 cc (IQR 262.5). In 16 cases (89%) treatment consisted solely of surgical resection; 2 cases required additional therapy: one received chemotherapy after surgery and another required chemotherapy plus whole brain radiotherapy for brain metastasis.
Histopathological study found 13 cases (72.2%) to be thymomas (type A in 30.8%, type AB 15.4%, type B1 46.1%, type B2 7.7%); 2 neuroendocrine tumors (11.1%), 1 thymic carcinoma (5.5%), 1 thymolipoma (5.5%) and 1 thymic cyst (5.5%) (Table 2), (Figs. 2, 3, 4, 5, 6, 7, 8, 9, 10).
Mean hospital admission length was 11.9 days; 3.3 days corresponded to intensive care unit (ICU) admission. There was only one mortality during hospitalization. After 1 month of surgery, 12 patients (66.6%) reported a significant clinical improvement during the follow up visit with the thoracic surgeon. The remaining 6 patients (33.3%) reported no change in their symptoms. The first patient had surgery on January 2011 and the last patient on May 2019, they were all followed until December 2019. Three patients died overall, and 5 patients were lost to follow up. A Kaplan-Meier curve was performed, estimating a survival probability of 81% at 5 years (Fig. 11).
As reported in the literature worldwide, the frequency of thymic tumors in both Latin America and Colombia is low; in fact, only 105 patients with thymomas were included in the multicenter study CLICaP-LATimus,  which was carried out from 1997 to 2018 in 7 Latin American countries (Mexico, Costa Rica, Colombia, Ecuador, Brazil, Peru and Argentina). In Colombia, a recent publication by Buitrago et al. reported 31 patients with thymic tumors who were treated at the National Institute of Cancerology (INC) between 2006 and 2017 .
The population described in our study was predominantly masculine, inconsistent with the gender distribution reported in the CLICaP-LATimus and the INC studies, were the proportion was inverted (40% men and 60% woman) [9, 10]. However, the mean age (52.7 years) was similar to the previous studies, unlike what has been reported in international cohorts, such as the European RARECAREnet projects (2000–20,007)  or the Japanese publication by Kanemura et al.,  in which patients were on average a decade older at diagnosis.
Inconsistent with previous evidence, 83.4% of patients were symptomatic at diagnosis, being dyspnea the most frequent manifestation. In this study, we found that 27.7% of patients presented with paraneoplastic syndromes, consistent with the frequency reported in the literature of 30–50% . Furthermore, paraneoplastic neuromuscular syndromes (myasthenia gravis, Eaton-Lambert syndrome, myotonic dystrophy, myositis, neuromyotonic, limbic encephalitis and stiff-person syndrome) are the most common similar to our findings, but hematological (RBC aplasia and pancytopenia), endocrine, dermatological and rheumatological disorders are also prevalent .
Symptomatic patients are more likely to have a chest image, facilitating diagnosis. Although a contrast enhanced chest computed tomography (CT) is the image of choice (Fig. 1),  cardiac or chest nuclear magnetic resonance imaging (NMRI) is useful in distinguishing compression from vascular invasion, in large lesions were this could be difficult to determine by CT. NMRI also allows the evaluation of the phrenic nerves and gives additional information about the involvement of the chest wall [13,14,15].
The National Comprehensive Cancer Network (NCCN) guidelines divide thymic cancers into three categories, according to the possibility of surgical resection. A total thymectomy and complete excision of the tumor without further treatment is the recommendation for TNM stage I tumors. When capsular invasion is present (stage II-IV) postoperative radiotherapy should be considered. For locally advanced tumors, the possibility of resection should be carefully considered by an experienced multidisciplinary team, and multimodal treatment with chemotherapy and/or radiotherapy is warranted . In our study 89% patients were managed with surgery alone, leaving no residual tumor, including 13 patients with stage I cancer, 1 patient with stage II (T2N0M0) and 1 patient with stage IVB (T3N2M0). The 2 remaining patients, who had separate pleural metastasis (T4N2M1a) and extrathoracic metastasis (T4N2M1b) affecting the brain, also underwent surgery but were offered additional oncologic treatment.
There are different surgical approaches to radical thymectomy, including cervicotomy, thoracotomy, sternotomy, video-assisted thoracoscopic surgery (VATS) (Fig. 9), and robotic assisted thoracoscopic surgery (RATS). All soft tissue should be removed in the anterior mediastinum between the phrenic nerves, which is key to control patients who present with myasthenia gravis and has been shown to positively impact mortality [17, 18]. Although the standard surgical technique is median sternotomy, since it allows a complete visualization of the mediastinum, pleural spaces, presence of capsular invasion or infiltration of near-by structures, VATS has been gaining popularity given that it is a minimally invasive procedure [17, 19]. VATS has been proved consistently to deliver best perioperative outcomes compared to open surgery, due to a reduced blood loss, shorter surgical time and hospitalization, better pain management and fewer postoperative infections. However, the oncological results of VATS are still controversial regarding the completeness of resection and recurrence rates, therefore its use is widely accepted for early stage thymomas (Masaoka-Koga I, II) . Nevertheless, Ning Xu et al., published a retrospective case report of 4 patients with stage III thymic tumors with invasion of the superior vena cava (SVC), who underwent VATS plus partial SVC resection without presenting major perioperative or postoperative complications, no mortality nor recurrence after 14 months of follow-up. These findings could be replicated by experienced centers worldwide giving hope to minimally invasive strategies . In our patients, thoracoscopy was the most utilized approach in 66.6% of cases. In our experience there were no intra or post operatory complications, even in patients who underwent sternotomy and thoracotomy.
Definitive diagnosis was made after surgical intervention in most cases, as in our patients, since the use of biopsy is only contemplated when there is suspicion of a differential diagnosis such as germ cell tumor or goiter . The World Health Organization (WHO) described a histopathological classification for thymomas, thymic carcinomas, thymic neuroendocrine tumors, among others. Specifically for thymomas, which are the most frequent, they are classified as type A, atypical type A variant, type AB, type B1-B3, micronodular thymoma with lymphoid stroma (MNT), metaplastic thymoma and other rare thymomas such as microscopic thymoma, sclerosing thymoma and lipofibroadenoma (Table 3) . In our experience, thymomas were the most common histopathological finding (72.2%), similar to the INC study which reported thymomas in 70.9% of cases . Our most frequent subtype was B1 (46.1%) followed by type A (30.8%).
Long-term survival of thymic tumors, particularly thymomas, tends to be favorable after radical resection. A retrospective analysis of 62 patients with thymomas who underwent thymectomy, reported an overall 5- and 10-year survival rate of 85.36 and 78.20%, respectively. In this cohort, patients < 50 years old, early Masaoka stages (I and II), histological type (type A, AB, B1) and lack of recurrence were independent prognostic factors of survival . In our experience, survival rate at 5 years was 81%, similar to the study cited earlier. We had three mortalities, of which 2 had disseminated disease.
Thymic tumors are unusual in the general population but represent half of tumors affecting the anterior mediastinum, of which thymomas are the most common. The treatment of choice is radical thymectomy, which has been shown to positively impact patient mortality. Although open surgery is the standard approach, VATS has been shown to be a safe and efficacious procedure and should be considered for this group of patients. While evidence suggests the majority of patients are asymptomatic, this was not our experience, facilitating early diagnosis and possibly increasing the survival probability of our patients.
Availability of data and materials
All data and material are available for sharing if needed with the Corresponding Author.
National Comprehensive Cancer Network
Red blood cell
- TNM staging:
Tumor, nodule, metastasis staging
Intensive care unit
National Institute of Cancerology
Nuclear Magnetic Resonance Imaging
Video-assisted thoracoscopic surgery
World Health Organization
Micronodular thymoma with lymphoid stroma.
Superior vena cava
Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of theLung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004.
Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer. 2003;105(4):546–51.
Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest. 2005;128(4):2893–909.
Patterson GA. Thymomas. Semin Thorac Cardiovasc Surg. 1992;4(1):39–44.
Scorsetti M, Leo F, Trama A, D’Angelillo R, Serpico D, Macerelli M, et al. Thymoma and thymic carcinomas. Crit Rev Oncol Hematol. 2016;99:332–50.
Chen J, Yang Y, Zhu D, Chen G, Wei S, Qiu X, et al. Thymoma with pure red cell aplasia and Good's syndrome. Ann Thorac Surg. 2011;91(5):1620–2.
Regnard JF, Zinzindohoue F, Magdeleinat P, Guibert L, Spaggiari L, Levasseur P. Results of re-resection for recurrent thymomas. Ann Thorac Surg. 1997;64(6):1593–8.
Bushan K, Sharma S, Verma H. A review of thymic tumors. Indian J Surg Oncol. 2013;4(2):112–6.
Mas L, Patané A, Arrieta OG, et al. Survival of Thymoma is extensive in Latin-American patients: results from over 10 years of experience (CLICaP-LATimus). J Thorac Surg. 2019;14(11):S1177–8.
Buitrago-Ramírez MR, Mantilla-Gaviria HJ, Carreño Dueñas JA. Tumores del timo: Experiencia del Instituto Nacional de Cancerología de Colombia. Rev Colomb Cancerol. 2019;23(3):92–8.
Siesling S, Van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesotelioma. Euro J Cancer. 2012;48(7):949–60.
Kanemura H, Tamura T, Nishimura N, et al. Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012–2014. Jpn J Clin Oncol. 2020;50(3):310–17.
Lichtenberger JP, Reynolds DA, Keung J, Keung E, Carter BW. Metastasis to the heart: a radiologic approach to diagnosis with pathologic correlation. AJR Am J Roentgenol. 2016;207(4):764–72.
Carter BW, Benveniste MF, Truong MT, Marom EM. State of the art: MR imaging of Thymoma. Magn Reson Imaging Clin N Am. 2015;23(2):165–77.
Rosado-de-Christenson ML, Strollo DC, Marom EM. Imaging of thymic epithelial neoplasms. Hematol Oncol Clin North Am. 2008;22(3):409–31.
National Comprehensive Cancer Network. Thymomas and Thymic Carcinomas (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. Accessed 20 Jan 2020.
Di Crescenzo VG, Napolitano F, Panico C, et al. Surgical approach in thymectomy: our experience and review of the literature. Int J Surg Case Rep. 2017;39:19–24. https://doi.org/10.1016/j.ijscr.2017.07.028.
León Atance P, González Aragoneses F, Moreno Mata N, et al. Timectomía en la miastenia gravis [Thymectomy in myasthenia gravis]. Arch Bronconeumol. 2001;37(5):235–9. https://doi.org/10.1016/s0300-2896(01)75060-0.
Raveglia F, Bertolaccini L, Solli P, et al. VATS thymectomy: oncological results and comparison between minimally invasive strategies. Shanghai Chest. 2018;2:1. https://doi.org/10.21037/shc.2018.01.03.
Xu N, Gu Z, Ji C, Zhang X, Chen T, Fang W. Thoracoscopic thymectomy with partial superior vena cava resection for locally advanced thymomas. J Thorac Dis. 2019;11(2):438–44. https://doi.org/10.21037/jtd.2018.12.120.
Hakiri S, Kawaguchi K, Fukui T, Nakamura S, Ozeki N, Mori S, et al. Verification of the diagnostic strategy for anterior mediastinal tumors. Int J Clin Oncol. 2018;0(0):0.
Marx A, Chan JK, Coindre JM, et al. The 2015 World Health Organization classification of tumors of the Thymus: continuity and changes. J Thorac Oncol. 2015;10(10):1383–95. https://doi.org/10.1097/JTO.0000000000000654.
Koçer B, Kaplan T, Günal N, et al. Long-term survival after R0 resection of thymoma. Asian Cardiovasc Thorac Ann. 2018;26(6):461–6. https://doi.org/10.1177/0218492318778634.
Administrative permits were not required to access the raw data prior to analysis within this study.
No funding sources were used.
Ethics approval and consent to participate
This manuscript was written in compliance with the ethical standards of the institutional ethics committee and with the 1964 Helsinki Declaration. We have approval of the Ethics Committee in Biomedical Research from Fundación Valle del Lili. This is supported in letter No. 260 of 2019. Act No. 15 of 2019, which is available if needed with the Corresponding Author. Consent to participate does not apply to this retrospective case study, approval was obtained from the ethics committee.
Consent for publication
Informed consent does not apply to this retrospective case study, approval was obtained from the ethics committee.
The authors declare that they have no competing interests. This manuscript has not been published and is not under consideration for publication elsewhere. Additionally, all of the authors have approved the contents of this paper and have agreed to the journal’s submission policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Scarpetta-Gonzalez, D.F., Morales, E.I., Sua, L.F. et al. Primary thymus tumors: retrospective case analysis at a reference center in Latin America, 2011–2019. BMC Cancer 21, 279 (2021). https://doi.org/10.1186/s12885-021-07920-7
- Thymic neoplasm
- Thymic carcinoma
- Video-assisted thoracoscopy
- Radical thymectomy